Safety of fenfluramine in children under 2 with Dravet syndrome
Part of Brain & nervous system clinical trials.
This trial tests the safety of a medicine called fenfluramine for children under 2 years old with Dravet syndrome. It aims to see if fenfluramine can help control seizures in very young children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 12 and 23 months old.
- Your child must have Dravet syndrome or a specific change in the SCN1A gene.
- Your child must have tried at least one seizure medicine (not a sodium channel blocker) that didn't work.
- Your child must not have certain heart valve problems (like mitral or aortic valve regurgitation).
- Your child must not have failure to thrive (very low weight or poor weight gain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if using a small, at-home EEG patch can help doctors adjust the dose of fenfluramine more safely and effectively for people with Dravet syndrome or Lennox-Gastaut syndrome. You may be eligible if you are starting fenfluramine for the first time.
This early-phase trial tests an experimental medicine called RC001 in children with Dravet syndrome caused by SCN1A gene changes. The goal is to see if RC001 is safe and how the body processes it, with the hope of reducing seizures.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
This study tests whether the drug fenfluramine can reduce the risk of sudden unexpected death (SUDEP) in people with Dravet syndrome who have generalized convulsive seizures. It aims to see if a lower dose can still prevent seizures and protect the heart and breathing during a seizure.
This Phase 2 trial studies fenfluramine to treat infantile spasms that haven’t improved after standard medicines (ACTH and vigabatrin). If you/your child has ongoing seizures, the study may offer another treatment option and will monitor safety closely, especially heart-related side effects.
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
Hear when a new Dravet Syndrome (DS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.